| Authors: |
Juric D; Mass General Cancer Center, Department of Medicine, Harvard Medical School, Boston, USA. Electronic address: Juric.Dejan@mgh.harvard.edu., Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., Reising A; Novartis Pharmaceuticals Corporation, East Hanover, USA., Vervier K; Novartis Pharma AG, Basel, Switzerland., Ma C; Novartis Pharmaceuticals Corporation, East Hanover, USA., Ciruelos EM; Medical Oncology, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain., Loibl S; Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany., Singer CF; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Sohn J; Yonsei Cancer Center, Seoul, Republic of Korea., Campone M; Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France., Conte P; S Camillo Hospital IRCCS, Lido of Venice, Venice, Italy., Iwata H; Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Ghaznawi F; Novartis Pharmaceuticals Corporation, East Hanover, USA., Miller M; Novartis Pharmaceuticals Corporation, East Hanover, USA., Taran T; Novartis Pharma AG, Basel, Switzerland., Su F; Novartis Pharmaceuticals Corporation, East Hanover, USA., André F; Medical Oncology, Institut Gustave Roussy, Villejuif, France. |
